FDA advisors to weigh whether Alzheimer’s drug Leqembi should receive full approval
A panel of independent advisors to the Food and Drug Administration is meeting Friday to make a recommendation on whether the Alzheimer's drug Leqembi, made by Eisai and Biogen, should receive full approval.The FDA is not required to follow…